JP Morgan Call 130 R66 17.01.2025/ DE000JL2EUR5 /
| 2024-07-29 10:47:09 AM | Chg.+0.03 | Bid10:00:38 PM | Ask10:00:38 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 2.19EUR | +1.39% | - Bid Size: - |
- Ask Size: - |
PHILLIPS 66 D... | 130.00 - | 2025-01-17 | Call |
GlobeNewswire
07-01
Phillips Edison & Company Announces Appointment of Devin Murphy to Board of Directors
GlobeNewswire
06-27
Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Inte...
GlobeNewswire
06-25
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technolog...
GlobeNewswire
06-20
The International Food Information Council (IFIC) Releases Annual Food & Health Survey Revealing Ris...
GlobeNewswire
06-17
Phillips Edison & Company Inc. Invites You to Join Its Second Quarter 2024 Earnings Conference Call
GlobeNewswire
06-17
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
06-12
Greystone Closes $22.9 Million in Total Debt Placement and Preferred Equity Financing for Fort Worth...
GlobeNewswire
06-05
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
05-29
Phillips Edison & Company to Present at Nareit REITweek 2024 Investor Conference
GlobeNewswire
05-22
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
GlobeNewswire
05-20
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease We...
GlobeNewswire
05-16
Optimal Daily Dairy Consumption Remains Elusive Despite Well-Established Health Benefits
GlobeNewswire
05-16
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
